EslicarTM (Eslicarbazepine acetate) is indicated as an add-on therapy for partial seizure with or without secondary generalization.
(in Tablet form)
EslicarTM(Eslicarbazepine acetate) must be added to existing anticonvulsant therapy. The recommended
starting dose is 400 mg once daily which should be increased to 800 mg once daily after one or two weeks. Based on individual response the dose may be increased to 1200 mg once daily.
Manufacturer: Square Pharmaceuticals Ltd.